Hesperadin Production Cost Reports

The report provides detailed analysis essential for establishing a hesperadin production plant. It encompasses all critical aspects necessary for hesperadin production, including the cost of hesperadin production, hesperadin plant cost, hesperadin production costs, and the overall hesperadin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a hesperadin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Hesperadin Market Analysis: Demand and Supply Analysis, and Sourcing

Hesperadin is a small-molecule inhibitor of Aurora B, a kinase that controls chromosome segregation during cell division. Hesperadin was developed by chemists at Boehringer Ingelheim. A 2003 paper in the Journal of Cell Biology, written mainly by company scientists in Germany and Austria, brought it to wider attention. The study showed how Aurora B corrects incorrectly attached chromosomes and helps maintain the spindle checkpoint during cell division. The paper continues to receive many citations. Structurally, hesperadin belongs to the indolinone chemical class, which also includes several marketed kinase drugs.

Demand for hesperadin is low but steady and mainly comes from cell biology research. Scientists studying cell division use it to quickly and reversibly block Aurora B at a specific time, which genetic methods cannot do in the same way. Cancer researchers use it to study abnormal cell division, polyploidy, checkpoint failure, and drug combinations. Parasitology researchers test it against Trypanosoma brucei, where it blocks the parasite's Aurora kinase and prevents nuclear division and cell separation. Virology researchers have also studied it as a potential broad-spectrum influenza compound that targets a host cell protein rather than the virus itself. These studies are still at the preclinical stage. Since each laboratory buys only milligram quantities, total global demand is estimated to be no more than a few kilograms. This keeps the price per gram high, and there is no large-scale market for the compound.

Supply comes from catalog houses and Chinese fine chemical makers. Merck sells it through its Calbiochem range, while Selleck, MedChemExpress, InvivoChem, and others list it for research. Fisher Scientific prices a 100 mg pack of the MedChemExpress grade at about 468 pounds. ChemicalBook lists more than fifteen Chinese suppliers, a few of them quoting kilogram and even tonne quantities, which almost certainly reflects capability rather than stock. A hesperadin demand and supply analysis has to weigh research budgets, the small order sizes, the wide gap between catalog and bulk pricing, and the lack of any regulated market.

Summary of the Product, Grades, and Uses

Hesperadin has the molecular formula C29H32N4O3S, a molar mass of 516.66 g/mol, and the CAS number 422513-13-1. Its chemical name describes an indolinone carrying an ethanesulfonamide at the 5-position and, at the 3-position, an exocyclic double bond bearing a phenyl group and an arylamino group. That aryl group is a phenyl ring with a piperidinylmethyl substituent. Only the Z isomer is the active compound, so the double bond geometry has to be controlled, proven, and maintained through storage. The solid is a light yellow to yellow crystalline powder that melts near 228 degree Celsius. Solubility is good in dimethyl sulfoxide at about 103 mg/mL, poor in ethanol, and effectively nil in water.

Hesperadin is available in three grades for different customers, each with its own documentation requirements. Standard research grade, with 98% purity by HPLC, is the most common and is sold in 1 mg, 5 mg, 10 mg, 50 mg, and 100 mg vials. High-purity grade, with 99% purity or higher and complete spectral data, is used in structural biology, screening libraries, reference standards, and assay development. Bulk or custom grade is supplied by Chinese manufacturers in quantities ranging from grams to kilograms for customers who need larger amounts for research, repackaging, or resale.

Each lot is tested for HPLC purity, identity by NMR, mass spectrometry, isomer ratio, water, and residual solvents. Appearance, color, and solubility in dimethyl sulfoxide are checked, since users dissolve it before every experiment. Suppliers advise storing the powder dry, dark, and at -20 degree Celsius, where it keeps about three years. Solutions keep far less well, roughly a year at -80 degree Celsius. Repeated freezing and thawing degrade them. Some catalogs also list a hydrochloride salt form, which handles and dissolves differently. Buyers should check which form they receive.

Main End-Uses of Hesperadin

Mitosis research is the core end-use for hesperadin, through university labs, cancer institutes, screening groups, and contract research organizations. Treating cells at 20 to 100 nM removes the mitotic phosphorylation of histone H3 at serine 10, which is the standard readout of Aurora B activity in fixed cells, live cells, and extracts. Cells then misalign their chromosomes, fail cytokinesis, become polyploid, and finally stop dividing altogether. At about 100 nM, it reverses the mitotic arrest caused by paclitaxel or by monastrol, though not the arrest caused by nocodazole. Treated cells also lose BubR1 and Bub1 from centromeres, which links Aurora B to checkpoint signaling.

Cancer research is the second main use of hesperadin, particularly in drug discovery groups, research laboratories, and screening centers. Researchers use it as a reference Aurora B inhibitor when testing newer compounds with more selective effects. Published studies have examined it alongside temozolomide, radiation, and other treatments in glioblastoma models. Its effects on other targets are also useful because, at 1 micromolar, it affects AMPK, Lck, MKK1, CHK1, and other kinases. This makes it useful for checking how selectively a compound acts, comparing results, and validating kinase screening tests.

Parasitology, virology & assay development complete demand for hesperadin. Against Trypanosoma brucei, it inhibits the parasite Aurora kinase, and it kills bloodstream forms at about 48 nM, far more potently than insect-stage forms at about 550 nM. Influenza researchers have used it to probe host kinase dependence, viral replication, and combination effects. Assay developers use it to validate kinase panels, cell-cycle readouts, and high-content imaging methods. Validation batches are usually small. Such buyers order single vials, usually once or twice a year. Repeat orders follow published papers.

Hesperadin Market Risks

Hesperadin faces risks because it is a research chemical with no clear path to becoming a medicine. Its development stopped before clinical trials, so there is no established regulatory approval process or reimbursement support. Newer Aurora inhibitors, including barasertib and alisertib, have more selective activity and more published research. Some have also reached clinical trials. Demand for hesperadin depends on research funding, publication trends, and interest in mitosis studies. Chinese suppliers offer low prices, putting pressure on profit margins for catalog products. Western suppliers compete by offering better customer service. Since the market is small, a single large customer can greatly affect a manufacturer's annual sales, making demand difficult to predict.

Manufacturing risks come from isomer control, color, purification, and scale. The exocyclic double bond can form as either isomer, and only one is wanted, so the condensation conditions must be tightly held. Strong color is another problem, since residual impurities show up as off-shade material that buyers reject on sight. Purification often needs chromatography at research scale, which is slow, solvent-hungry, and does not transfer well to kilograms. Polarity from the sulfonamide and aminomethyl groups complicates crystallization. Solvent screening is usually needed. Batches fail mainly on purity, isomer ratio, color, or residual solvents. Reprocessing is possible but costly.

Hesperadin Production Process and Main Cost Drivers

The hesperadin production process runs from 5-aminooxindole and ethanesulfonyl chloride through sulfonamide formation, acylation at the oxindole 3-position, condensation with the substituted aniline, isomer control, crystallization, drying, and packing into small vials.

1. By Condensation of a 3-Acylated Oxindole Sulfonamide with a Piperidinylmethyl Aniline: The main inputs are 5-aminooxindole, ethanesulfonyl chloride, a benzoyl source, 4-nitrobenzaldehyde, piperidine, a reducing agent, pyridine or another base, acetic acid, alcohols, chromatography media, and packaging.

Hesperadin production builds two fragments, purifies each one, and then joins them. First comes the oxindole core. 5-Aminooxindole reacts with ethanesulfonyl chloride in the presence of a base, which puts the ethanesulfonamide onto the aromatic amine. The oxindole 3-position, which sits between a carbonyl and an aromatic ring, is acidic enough to be acylated. A benzoyl group is introduced there, giving a 3-benzoyl oxindole that exists largely as its enol tautomer.

The next stage involves making the aniline component. 4-Nitrobenzaldehyde reacts with piperidine to form nitrobenzylpiperidine. The nitro group is then reduced to produce 4-(piperidin-1-ylmethyl)aniline. This aniline reacts with 3-benzoyl oxindole, releasing water and forming the enaminone structure that defines hesperadin. The reaction is usually carried out in alcohol or acetic acid with heating. The Z isomer is favored because of an internal hydrogen bond. The product is then purified by chromatography or crystallization, dried, lightly milled, and filled into vials under dry conditions. Isomer purity, color, and overall yield are the main factors affecting conversion costs. Losses at each stage also increase the cost of the final product.

Main Factors Affecting Hesperadin Production Cost

Hesperadin production cost is shaped mainly by small batch sizes rather than by raw materials. By stoichiometry, each kilogram of hesperadin needs about 0.29 kg of 5-aminooxindole, 0.25 kg of ethanesulfonyl chloride, 0.37 kg of the piperidinylmethyl aniline, and 0.27 kg of a benzoyl source. Real-world use runs several times higher across the route. 5-Aminooxindole is the costliest building block, since it is a specialty heterocycle rather than a commodity. Buyers can purchase the aniline fragment or make it in-house, and making it adds two steps but cuts cost at volume.

The remaining costs mainly come from labor, purification, testing, and packaging. Producing a few hundred grams requires almost the same setup, cleaning, documentation, and quality checks as a much larger batch. When chromatography is used, it consumes large amounts of silica and solvent compared with the final product weight. Each batch must undergo HPLC, NMR, mass spectrometry, water content, and solvent testing before approval. Filling small amounts into labeled and barcoded vials also requires time-consuming manual work. Automation is rarely cost-effective at this production scale. As a result, catalog prices are much higher than the basic chemical production cost. Documentation and customer service account for much of this price difference.

Raw Materials for Hesperadin Production Plant and its Procurement

Raw material sourcing for hesperadin mainly involves 5-aminooxindole, the aniline component, and standard chemical reagents. 5-Aminooxindole is supplied by heterocycle manufacturers in China and India and is usually made by reducing 5-nitrooxindole using palladium, iron, or tin. 4-Nitrobenzaldehyde, piperidine, and reducing agents are common fine chemicals available from many suppliers. Ethanesulfonyl chloride is purchased from specialist manufacturers and must be handled in dry conditions. Benzoylating agents, bases, alcohols, acetic acid, and drying agents are available from regular chemical distributors. Silica gel, chromatography cartridges, and purification solvents are bought in bulk. Used silica is sent to licensed waste disposal facilities.

Raw material quality affects production yield, color, and isomer purity. 5-Aminooxindole must contain low levels of the nitro starting material, dimers, tar-like impurities, and colored oxidation products. The aniline component must be free of the nitro compound and unwanted positional isomers. Ethanesulfonyl chloride reacts with moisture, so it must be shipped and stored in dry conditions. Its drums are kept sealed under nitrogen. Supplier contracts set limits for purity, water content, color, isomers, and related impurities. Each batch is sampled, tested, and approved before use. Having a second supplier for the oxindole helps prevent production delays.

Sustainability and Regulatory Requirements

Hesperadin production requires careful handling of solvents, chromatography waste, and sulfonyl chloride. Chromatography produces large amounts of silica containing solvents, which must be sent for approved disposal, solvent recovery, or incineration. Recovering solvents is worthwhile even on a small scale because the process uses significant amounts of ethyl acetate, heptane, and alcohol for each gram of product. Ethanesulfonyl chloride releases hydrogen chloride when it comes into contact with water, so gas vents need scrubbers to control emissions. Used reaction liquids contain amines, aromatic compounds, and salts, which must be treated before discharge. Small production batches keep the total waste volume low, but all waste must still be separated and tracked.

Hesperadin is regulated as a research chemical, not a medicine. It has no pharmacopoeial monograph and does not need marketing approval because it is sold only for laboratory use. Suppliers label it under GHS rules and ship it under standard chemical transport requirements, usually at room temperature with ice packs. In the EU, manufacturers and importers handling more than one tonne per year must register it under REACH, although current volumes are much lower. In the US, research exemptions under TSCA and OSHA hazard communication rules may apply. Buyers expect each batch to include a certificate of analysis, spectral data, chromatograms, and a safety data sheet. Manufacturers planning to supply hesperadin for drug development would need to follow ICH Q7 quality guidelines.

CAPEX and OPEX for a Hesperadin Production Plant

A hesperadin plant is usually a small, multi-purpose chemical facility rather than a dedicated production unit. The setup cost includes glass or glass-lined reactors with capacities of 20 to 200 liters for the sulfonamide, acylation, and condensation steps. Dry charging systems, nitrogen lines, and sealed funnels are used to handle sulfonyl chloride safely. Nutsche filters, rotary evaporators, and vacuum dryers are used to separate, concentrate, and dry the product. Purification requires chromatography and solvent recovery equipment. Filling small vials requires a clean area with weighing balances, dry air, and labeling equipment. Utilities include nitrogen, chilled brine, steam, vacuum systems, and scrubbers. The quality control laboratory needs HPLC, access to LC-MS and NMR testing, a Karl Fischer instrument, gas chromatography for solvent testing, and a melting point apparatus.

Hesperadin operating costs mainly come from labor, solvents, purification materials, and testing. Raw materials, vials, labels, and moisture-absorbing packs add smaller costs that vary with production volume. Energy is mainly used for distillation, drying, cooling, and solvent recovery. Fixed costs include equipment depreciation, equipment use, quality systems, insurance, and documentation. Sharing the facility with other research chemicals can greatly reduce the cost per gram. Most catalog suppliers use this approach. Producing enough material to meet several years of expected demand in one batch can also reduce costs, but stored material must be tested again before use.

Plant Location and Investment Factors

A hesperadin plant should be located near fine chemical suppliers, custom synthesis companies, and chemical distributors. In China, Shanghai, Jiangsu, and Hubei have many suppliers and manufacturers of heterocyclic intermediates. Hyderabad and Gujarat in India offer custom synthesis services at competitive prices. Europe and the US have suppliers that repackage hesperadin, prepare its documents, and distribute it to researchers. The plant needs facilities for handling dry solvents, chromatography equipment, and analytical testing.

For a hesperadin project, the first investment decision is the business model. Making bulk compounds for catalog houses is a different business from selling vials to researchers. Margins differ sharply between the two. Purification method is the second decision, from chromatography to crystallization. Investing in crystallization development removes chromatography and transforms the cost at scale. Product range, from one molecule to a catalog of hundreds, is the third decision. Hesperadin alone cannot support a plant. Hesperadin fits only as one item in a catalog of kinase inhibitors & other research compounds.

Major Hesperadin Producing Regions

China is currently the main source of hesperadin, with more than 15 listed suppliers across Shanghai, Beijing, Wuhan, Hubei, and Chengdu. Some suppliers offer quantities ranging from grams to kilograms or more, indicating their production capacity rather than confirmed stock availability. In Germany, Merck sells the compound through its Calbiochem range. Selleck, MedChemExpress, and other US-based catalog suppliers serve research customers worldwide. Boehringer Ingelheim, which has sites in Germany and Austria, developed the compound but does not sell it. India offers cost-effective custom synthesis services for this type of molecule. Most research demand comes from North America, Europe, Japan, and China, with academic laboratories accounting for the largest share.

Key Hesperadin Producers

Merck KGaA

• German science and technology group selling hesperadin through its Calbiochem research brand.
• Supplies it in small vials for cell biology and kinase research.
• Competes on brand trust, documentation & global laboratory distribution.
• Lists it as an Aurora B inhibitor for research use only.

MedChemExpress

• US-based supplier of bioactive compounds and inhibitors for research.
• Sells hesperadin at 98% purity in 5 mg to 100 mg packs.
• Competes on catalog breadth, price & fast delivery through distributors.
• Its 100 mg pack lists at about 468 pounds through Fisher Scientific.

Selleck Chemicals

• Supplier of inhibitors and screening compounds for drug discovery.
• Sells hesperadin under catalog number S1529 with published protocols.
• Competes on technical datasheets, protocol support & screening libraries.
• Lists solubility of 103 mg/mL in dimethyl sulfoxide.

InvivoChem

• US supplier of research compounds, including in vivo-ready formulations.
• Sells hesperadin at 98% or better purity with suggested dosing vehicles.
• Competes on animal study support & formulation guidance.
• Supplies cancer biology and parasitology researchers.

Chinese Fine Chemical Suppliers

• Numerous firms in Shanghai, Wuhan, Hubei, and elsewhere listed on ChemicalBook.
• Offer purities from 95% to 99% in quantities from milligrams upward.
• Compete on cost, custom synthesis & willingness to scale.
• Supply both end users and the catalog brands that repack material.

Boehringer Ingelheim

• German pharmaceutical company whose chemists created hesperadin.
• Published the 2003 study that established the compound as an Aurora B tool.
• Developed it within an indolinone kinase inhibitor program.
• Does not market the compound, which remained a research molecule.